Celsion Corporation  

(Public, NASDAQ:CLSN)   Watch this stock  
Find more results for Donald Yu�
1.10
+0.02 (1.85%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.04 - 1.16
52 week 1.04 - 3.57
Open 1.08
Vol / Avg. 253,482.00/101,565.00
Mkt cap 25.80M
P/E     -
Div/yield     -
EPS -1.13
Shares 23.24M
Beta 2.14
Inst. own 20%

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -3413.93% -5098.85%
Operating margin -3167.33% -4900.25%
EBITD margin - -4592.12%
Return on average assets -30.01% -45.38%
Return on average equity -63.17% -79.24%
Employees 28 -
CDP Score - -

Address

997 Lenox Dr Ste 100
LAWRENCE TOWNSHIP, NJ 08648-2317
United States - Map
+1-609-8969100 (Phone)
+1-609-8962200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Celsion Corporation (Celsion) is an oncology drug development company. The Company is focused on developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and ribonucleic acid (RNA)- or deoxyribonucleic acid (DNA)-based therapies. Its lead program is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. The Company has three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence.

Officers and directors

Jeffrey Wayne Church CPA Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer
Age: 58
Bio & Compensation  - Reuters
Khursheed Anwer Ph.D. Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy
Age: 55
Bio & Compensation  - Reuters
Nicholas Borys M.D. Senior Vice President and Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Michael H. Tardugno Executive Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Donald Braun Ph.D. Independent Director
Bio & Compensation  - Reuters
Pok Yu Chow Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Frederick J. Fritz Independent Director
Age: 64
Bio & Compensation  - Reuters
Robert W. Hooper Independent Director
Age: 68
Bio & Compensation  - Reuters
Alberto R. Martinez M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters